mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
about
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalingThe substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus.Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.Development of allosteric modulators of GPCRs for treatment of CNS disordersMetabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Therapeutic potential of metabotropic glutamate receptor modulators.Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Glutamate receptors as therapeutic targets for Parkinson's disease.Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseMavoglurant as a treatment for Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Non-human primate models of PD to test novel therapies.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.Metabotropic glutamate receptors for Parkinson's disease therapy.Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primatesPharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice.Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate ReceptorsL-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
P2860
Q26852311-A9E49634-38FB-42B6-BF9E-46CA8E405C56Q30833645-84D21A3E-6713-42FF-B97B-D66E2C05C496Q33428476-EE5BA29F-9B5F-4BDB-909D-7EAC71C76755Q33707910-D3BE56B5-FD33-4C16-A00D-57A6B2A14F21Q34368806-DBC8A13F-6A57-40D7-9FE2-068C0C6D06C7Q34373958-3A145923-CFA7-49FD-8E9E-131C6A53C23AQ34429155-DB50089D-A6C2-43CF-BBAC-ACF2E33ABD2AQ35614156-82A91105-7FB7-495C-A241-EC74362AAE43Q35778704-6F1279A6-A518-4806-AA35-FA7689CB1C43Q36851672-ADEC96FF-B9AB-4C7C-B361-0614CB8841F8Q37384351-C80812EB-FE27-4083-9C8B-19000510CDE1Q37506507-4801A3D7-9D63-49EB-AFC6-C5B67C5F3DBBQ37585401-ADB2CC8E-01F6-42FA-8283-49948429DEE4Q37656643-A34C6840-0735-49AC-91E9-D64E26E4DC0CQ37924629-AD2115E0-BD0B-42AE-961B-0A637EB791B1Q37974709-73CD8658-73E3-4624-A198-471F10F85A00Q38056852-85081B54-B668-489E-8AE9-25BEB476467FQ38092819-F339F927-5CF0-498C-B43B-AAF3B219773FQ38190016-EC316A6C-6C1D-410E-81ED-B0CCB38BA9A1Q38218083-9B6707E7-8935-43FC-8F0C-F5AFA45F9D50Q38222814-CA61423C-2B0D-4FE3-BACE-E38FA89CBC27Q38262418-ED1233CD-9DB8-4F34-99F0-7EEE6AC973AAQ38355582-0110D5B4-AE89-4C68-9451-7A6CAB369397Q38658203-66D51584-11E5-43CB-B146-9566F1A2DD97Q38660240-BFD478DC-3DE3-46D0-AE68-7B355F9A4248Q39229450-3F819C12-9112-495B-ABCF-AA9FBED92918Q39324877-6341C345-E01F-45EA-8A73-F742DCA9471EQ39384819-E8BBCDC5-12F9-4734-8EC6-1F6CFEED2A48Q41818450-E18EB7E3-92C6-42E9-B67C-4C0A01F3381EQ42434375-B9CBDF21-2058-4DD2-8908-0421217F4875Q42777922-7A138C6E-3CD9-4014-9786-4B36449A3B17Q43219126-C03A64CF-C7F5-4082-BDC9-053B9B8643E5Q44050418-258F0045-B53B-4805-99A1-BE9B6A68932DQ50773434-9FA779BF-DB73-4F30-83C8-F7CE970190AFQ51750611-84DD43F8-AD64-43B0-860E-2BF0B8DFF103Q58694067-014A0EBB-30F6-4EA0-9151-F6B69EAF0817Q59136653-23EC7A2E-F2F9-4677-A3F5-EBBCBBADB8D2
P2860
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@en
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@nl
type
label
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@en
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@nl
prefLabel
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@en
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@nl
P2093
P1476
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.
@en
P2093
Abdallah Hadj Tahar
Fréderic Calon
Laurent Grégoire
Leonard T Meltzer
Marc Morissette
Mehdi Dridi
Nancy Belanger
Paul J Bédard
Pershia Samadi
P304
P356
10.1016/J.NEUROBIOLAGING.2007.02.005
P577
2007-03-13T00:00:00Z